



Sumavel[®] DosePro[®] (sumatriptan) – Product Discontinuation

- On October 17, 2016, the [FDA announced](#) the discontinuation of Endo's [Sumavel DosePro \(sumatriptan\)](#) 4 mg/0.5 mL injection.
 - The discontinuation is not due to product quality, safety, or efficacy concerns.
 - The Sumavel DosePro 6 mg/0.5 mL injection will remain available.
- Sumavel DosePro is indicated in adults for the acute treatment of migraine, with or without aura, and the acute treatment of cluster headache.
 - Sumavel DosePro should only be used only if a clear diagnosis of migraine or cluster headache has been established.
 - If a patient has no response to the first migraine attack treated with Sumavel DosePro, the diagnosis of migraine should be reconsidered before Sumavel DosePro is administered to treat any subsequent attacks.
 - Sumavel DosePro is not indicated for the prevention of migraine attacks.
- For additional questions, contact Endo at **1-800-462-3636**.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News[®] is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.